Table 1 Risk of amputation, PAD and DF events in patients with SGLT2i treatment
From: SGLT2 inhibitors and lower limb complications: an updated meta‐analysis
Subgroup | No. of participants (SGLT2i/control) | OR | 95% CI | P value | I2 (%) |
|---|---|---|---|---|---|
Risk of amputation by SGLT2i subtypes | |||||
In total* | 40,925/33,414 | 1.23 | 1.08, 1.40 | 0.002 | 2 |
Canagliflozin* | 7992/6543 | 1.60 | 1.04, 2.46 | 0.03 | 67 |
Dapagliflozin | 13,394/13,236 | 1.08 | 0.85, 1.37 | 0.54 | 0 |
Empagliflozin | 7101/4467 | 1.07 | 0.76, 1.49 | 0.71 | 0 |
Ertugliflozin | 5493/2745 | 1.24 | 0.87, 1.76 | 0.23 | NA |
Sotagliflozin | 6945/6423 | 1.08 | 0.68, 1.70 | 0.75 | 0 |
Risk of amputation by study types | |||||
CVOT and ROT* | 39,025/32,473 | 1.23 | 1.07, 1.40 | 0.003 | 29 |
Efficacy and safety evaluation | 1900/941 | 1.74 | 0.36, 8.39 | 0.49 | 0 |
Risk of amputation by population | |||||
DM only* | 34,872/27,196 | 1.24 | 1.08, 1.42 | 0.002 | 14 |
Including patients without DM | 6383/6386 | 1.08 | 0.62, 1.88 | 0.78 | 0 |
Risk of amputation by control types | |||||
Active agent | 551/267 | 1.46 | 0.06, 35.90 | 0.82 | NA |
Placebo* | 40,374/33,147 | 1.23 | 1.08, 1.40 | 0.002 | 9 |
Risk of amputation by study duration | |||||
< 26 weeks | 300/148 | 2.49 | 0.12, 52.14 | 0.56 | 0 |
26–52 weeks | 2205/1404 | 2.34 | 0.58, 9.52 | 0.23 | 0 |
> 52 weeks* | 33,129/26,576 | 1.24 | 1.08, 1.43 | 0.002 | 33 |
Risk of PAD by SGLT2i subtypes | |||||
In total* | 36,446/28,685 | 1.21 | 1.03, 1.42 | 0.02 | 0 |
Canagliflozin* | 10,467/7967 | 1.53 | 1.14, 2.05 | 0.005 | 0 |
Dapagliflozin | 15,668/14,657 | 1.03 | 0.81, 1.30 | 0.83 | 0 |
Empagliflozin | 7999/4558 | 1.26 | 0.88, 1.78 | 0.20 | 0 |
Ertugliflozin | 1613/800 | 1.50 | 0.30, 7.43 | 0.62 | 0 |
Sotagliflozin | 699/703 | 0.33 | 0.01, 8.23 | 0.50 | NA |
Risk of PAD by study types | |||||
CVOT and ROT* | 25,773/21,964 | 1.24 | 1.05, 1.46 | 0.01 | 6 |
Efficacy and safety evaluation | 10,673/6721 | 0.96 | 0.55, 1.68 | 0.90 | 0 |
Risk of PAD by population | |||||
DM only* | 31,926/24,166 | 1.23 | 1.03, 1.45 | 0.02 | 0 |
Including patients without DM | 4520/4519 | 1.10 | 0.67, 1.79 | 0.71 | 0 |
Risk of PAD by control types | |||||
Active agent | 3856/2619 | 1.00 | 0.33, 3.06 | 1.00 | 0 |
Placebo* | 32,590/26,066 | 1.22 | 1.03, 1.43 | 0.02 | 0 |
Risk of PAD by study duration | |||||
< 26 weeks | 5043/3159 | 0.91 | 0.43, 1.90 | 0.80 | 0 |
26–52 weeks | 2766/1725 | 1.70 | 0.50, 5.76 | 0.40 | 0 |
> 52 weeks* | 28,637/23,801 | 1.22 | 1.03, 1.44 | 0.02 | 0 |
Risk of DF by SGLT2i subtypes | |||||
In total | 31,907/25,570 | 1.24 | 0.93, 1.64 | 0.14 | 0 |
Canagliflozin | 9139/7115 | 1.55 | 0.94, 2.54 | 0.09 | 0 |
Dapagliflozin | 14,638/13,809 | 1.20 | 0.79, 1.83 | 0.40 | 0 |
Empagliflozin | 7029/4055 | 0.90 | 0.48, 1.67 | 0.74 | 0 |
Ertugliflozin | 1201/591 | 1.48 | 0.15, 14.28 | 0.73 | 0 |
Risk of DF by study types | |||||
CVOT and ROT | 25,773/21,964 | 1.23 | 0.91, 1.66 | 0.17 | 0 |
Efficacy and safety evaluation | 6134/3606 | 1.26 | 0.55, 2.92 | 0.59 | 0 |
Risk of DF by population | |||||
DM only | 27,387/21,051 | 1.28 | 0.95, 1.72 | 0.11 | 0 |
Including patients without DM | 4520/4519 | 0.89 | 0.34, 2.31 | 0.81 | 0 |
Risk of DF by control types | |||||
Active agent | 4173/2467 | 1.54 | 0.44, 5.34 | 0.50 | 0 |
Placebo | 27,734/23,103 | 1.22 | 0.91, 1.63 | 0.18 | 0 |
Risk of DF by study duration | |||||
< 26 weeks | 1131/562 | 1.49 | 0.23, 9.51 | 0.67 | 0 |
26–52 weeks | 2940/1614 | 1.51 | 0.44, 5.16 | 0.51 | 0 |
> 52 weeks | 27,836/23,394 | 1.22 | 0.91, 1.63 | 0.19 | 0 |